ReviewMolecular diagnosis & therapy2016
Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy.
Review in Molecular diagnosis & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS.Clinical pharmacology and therapeutics · 2026Article
- Article
- Article
- Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Ras-related protein Rab24 plays a predictive role in hepatocellular carcinoma and enhanced tumor proliferation.World journal of gastroenterology · 2025Article
- Inhibiting Rac1 signaling alleviates DSS-induced colitis by improving inflammatory response and intestinal permeability.Gastroenterology report · 2025Article
- A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients.Scientific reports · 2022Article
- Identification of shared and disease-specific host gene-microbiome associations across human diseases using multi-omic integration.Nature microbiology · 2022Article
- Review
- TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India.BMC gastroenterology · 2021Article
- Targeted intestinal deletion of Rho guanine nucleotide exchange factor 7, βPIX, impairs enterocyte proliferation, villus maturation, and mucosal defenses in mice.American journal of physiology. Gastrointestinal and liver physiology · 2021Article
- Gut microbiota-driven drug metabolism in inflammatory bowel disease.Journal of Crohn's & colitis · 2021Article
- Review
- A Nucleotide Analog Prevents Colitis-Associated Cancer via Beta-Catenin Independently of Inflammation and Autophagy.Cellular and molecular gastroenterology and hepatology · 2021Article
- The Ugly Duckling of Thiopurines Becomes the Beautiful Swan of Colitis-associated Cancer Management.Cellular and molecular gastroenterology and hepatology · 2021Article
- Curcumin and resveratrol suppress dextran sulfate sodium‑induced colitis in mice.Molecular medicine reports · 2019Article
- Inhibition of Rac family protein impairs colitis and colitis-associated cancer in mice.American journal of cancer research · 2018Article
- Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease.Therapeutic drug monitoring · 2017Review
- Structures of a DNA Polymerase Inserting Therapeutic Nucleotide Analogues.Chemical research in toxicology · 2017Article
- A functional genomics predictive network model identifies regulators of inflammatory bowel disease.Nature genetics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence and prevalence of inflammatory bowel disease (IBD) are increasing. Although the etiology of IBD is unknown, it is thought that genetically susceptible individuals display an inappropriate inflammatory response to commensal microbes, resulting in intestinal tissue damage. Key proteins involved in regulating the immune response, and thus in inflammation, are the small triphosphate-binding protein Rac and its regulatory network. Recent data suggest these proteins to be involved in (dys)regulation of the characteristic inflammatory processes in IBD. Moreover, Rac-gene variants have been identified as susceptibility risk factors for IBD, and Rac1 GTPase signaling has been shown to be strongly suppressed in non-inflamed mucosa compared with inflamed colonic mucosa in IBD. In addition, first-line immunosuppressive treatment for IBD includes thiopurine therapy, and its immunosuppressive effect is primarily ascribed to Rac1 suppression. In this review, we focus on Rac modification and its potential role in the development of IBD, Rac as the molecular therapeutic target in current thiopurine therapy, and the modulation of the Rac signal transduction pathway as a promising novel therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.